Company news
Vanda Pharmaceuticals Inc. news in 2023
Vanda Pharmaceuticals Inc.'s news releases, calls and decks from 2023, newest first.
Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis
December 6, 2023
Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis
December 3, 2023
Vanda Pharmaceuticals Announces Participation at November 2023 Investor Conferences
November 8, 2023
Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results
November 7, 2023
Vanda Pharmaceuticals to Announce Third Quarter 2023 Financial Results on November 8, 2023
October 31, 2023
Vanda Pharmaceuticals Intends to Petition the U.S. Supreme Court in its HETLIOZ® ANDA Litigation
October 19, 2023
Vanda Pharmaceuticals Announces Participation in the Jefferies Inaugural Biotech CNS/Neuro Summit
October 4, 2023
Vanda Pharmaceuticals Reports Second Quarter 2023 Financial Results
July 26, 2023
Vanda Pharmaceuticals to Announce Second Quarter 2023 Financial Results on July 27, 2023
July 19, 2023
Vanda Pharmaceuticals Announces Participation in the Jefferies 2023 Global Healthcare Conference
June 4, 2023
Vanda Pharmaceuticals Announces Presentations at SLEEP 2023
May 31, 2023
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S
May 31, 2023
Vanda Pharmaceuticals Reports Results from a Phase III study of Tradipitant in Motion Sickness
May 24, 2023
Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Appeal
May 9, 2023
Vanda Pharmaceuticals Announces Presentations at DDW 2023
May 3, 2023
Vanda Pharmaceuticals Reports First Quarter 2023 Financial Results
May 2, 2023
Vanda Pharmaceuticals Sues Federal Government for Misappropriation of Trade Secrets and Confidential Information
May 1, 2023
Vanda Pharmaceuticals to Announce First Quarter 2023 Financial Results on May 3, 2023
April 26, 2023
Vanda Prevails in Jet Lag Litigation Against the FDA
March 27, 2023
Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors
March 16, 2023
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
February 7, 2023
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 8, 2023
January 31, 2023
Calls in 2023
- Vanda Pharmaceuticals (NASDAQ:VNDA) Q3 2023 Earnings Call
Nov 8, 2023
Transcript - Vanda Pharmaceuticals (NASDAQ:VNDA) Q2 2023 Earnings Call
Jul 27, 2023
Transcript - Vanda Pharmaceuticals (NASDAQ:VNDA) Q1 2023 Earnings Call
May 4, 2023
Transcript - Vanda Pharmaceuticals (NASDAQ:VNDA) Q4 2022 Earnings Call
Feb 8, 2023
Transcript
Decks in 2023
- Investor Presentation (November 2023)
Investor deck · 59 slides · November 2023
- Investor Presentation (September 2023)
Investor deck · 59 slides · September 2023